| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
8,397 |
6,385 |
$817K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
10,674 |
8,883 |
$770K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
493 |
427 |
$733K |
| 80053 |
Comprehensive metabolic panel |
10,958 |
8,817 |
$618K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
6,760 |
1,060 |
$462K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
617 |
479 |
$447K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,129 |
826 |
$353K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,916 |
1,315 |
$269K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
10,230 |
974 |
$258K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,222 |
7,783 |
$212K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,684 |
1,651 |
$204K |
| 71046 |
Radiologic examination, chest; 2 views |
2,442 |
1,893 |
$187K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,344 |
2,543 |
$179K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,436 |
1,982 |
$167K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,420 |
1,958 |
$152K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,492 |
1,736 |
$151K |
| 36415 |
Collection of venous blood by venipuncture |
18,587 |
11,506 |
$134K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,573 |
1,663 |
$125K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,205 |
940 |
$124K |
| 71045 |
Radiologic examination, chest; single view |
2,249 |
1,759 |
$115K |
| 80061 |
Lipid panel |
3,230 |
2,950 |
$113K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
730 |
673 |
$104K |
| 90837 |
Psychotherapy, 53 minutes with patient |
2,382 |
757 |
$85K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
486 |
298 |
$75K |
| 80306 |
|
2,036 |
1,631 |
$72K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,107 |
923 |
$72K |
| 84484 |
|
2,279 |
1,770 |
$71K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
821 |
609 |
$70K |
| 87088 |
|
2,597 |
2,090 |
$70K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,946 |
2,138 |
$59K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,510 |
2,273 |
$56K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,825 |
1,399 |
$51K |
| 81001 |
|
3,561 |
2,936 |
$44K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
826 |
728 |
$41K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,399 |
1,122 |
$36K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,106 |
780 |
$29K |
| 83735 |
|
1,584 |
1,220 |
$27K |
| 83690 |
|
1,898 |
1,486 |
$25K |
| 81003 |
|
3,253 |
2,711 |
$22K |
| 81025 |
|
878 |
709 |
$22K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,450 |
1,279 |
$19K |
| 72100 |
|
185 |
161 |
$18K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
702 |
622 |
$18K |
| 84443 |
Thyroid stimulating hormone (TSH) |
493 |
461 |
$16K |
| 82150 |
|
751 |
572 |
$16K |
| 97161 |
|
255 |
200 |
$15K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
129 |
100 |
$14K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,809 |
1,493 |
$14K |
| 73630 |
|
133 |
118 |
$13K |
| 87077 |
|
625 |
501 |
$13K |
| 87186 |
|
490 |
432 |
$11K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
470 |
415 |
$11K |
| 85610 |
|
718 |
517 |
$10K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,263 |
1,675 |
$9K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
611 |
493 |
$9K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
835 |
429 |
$8K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,075 |
822 |
$7K |
| 73610 |
|
59 |
52 |
$6K |
| 85730 |
|
316 |
255 |
$5K |
| 83880 |
|
102 |
87 |
$5K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
23 |
14 |
$5K |
| 82607 |
|
184 |
172 |
$5K |
| 0012A |
|
262 |
193 |
$5K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
173 |
157 |
$5K |
| 73030 |
|
53 |
29 |
$4K |
| 85378 |
|
72 |
61 |
$4K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
17 |
15 |
$4K |
| J2704 |
Injection, propofol, 10 mg |
253 |
198 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
135 |
110 |
$4K |
| 0011A |
|
287 |
213 |
$4K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
117 |
91 |
$3K |
| 80305 |
|
146 |
90 |
$3K |
| 84439 |
|
152 |
136 |
$3K |
| 82043 |
|
285 |
259 |
$3K |
| 72110 |
|
20 |
15 |
$3K |
| 87634 |
|
52 |
49 |
$3K |
| 83605 |
|
125 |
87 |
$2K |
| 90734 |
|
17 |
15 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
40 |
37 |
$2K |
| 86757 |
|
24 |
12 |
$2K |
| 85652 |
|
91 |
79 |
$2K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
143 |
111 |
$2K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
326 |
227 |
$2K |
| 0013A |
|
60 |
59 |
$1K |
| 73130 |
|
17 |
15 |
$1K |
| 83874 |
|
29 |
24 |
$1K |
| 90688 |
|
86 |
61 |
$1K |
| 80320 |
|
53 |
38 |
$1K |
| Q3014 |
Telehealth originating site facility fee |
44 |
15 |
$1K |
| 90633 |
|
27 |
27 |
$1K |
| 87807 |
|
28 |
26 |
$991.28 |
| 0002A |
|
33 |
31 |
$974.77 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
122 |
81 |
$955.04 |
| 90694 |
|
14 |
14 |
$929.68 |
| 90832 |
Psychotherapy, 30 minutes with patient |
59 |
14 |
$914.18 |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
67 |
44 |
$883.14 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
13 |
12 |
$795.13 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
13 |
12 |
$792.13 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
27 |
26 |
$774.34 |
| 90674 |
|
23 |
21 |
$759.32 |
| 84702 |
|
15 |
12 |
$734.11 |
| 86738 |
|
21 |
13 |
$559.31 |
| J7050 |
Infusion, normal saline solution, 250 cc |
184 |
119 |
$444.84 |
| 96376 |
|
20 |
13 |
$426.30 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
13 |
12 |
$385.45 |
| 0001A |
|
25 |
18 |
$338.14 |
| 82803 |
|
19 |
12 |
$306.98 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
57 |
50 |
$297.74 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
170 |
133 |
$266.05 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
17 |
15 |
$265.41 |
| 36600 |
|
19 |
12 |
$204.18 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
21 |
13 |
$178.28 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
36 |
12 |
$32.04 |
| 91301 |
|
705 |
493 |
$20.34 |
| Q0245 |
Injection, bamlanivimab and etesevimab, 2100 mg |
18 |
15 |
$4.17 |
| A9270 |
Non-covered item or service |
371 |
89 |
$0.00 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
15 |
13 |
$0.00 |
| 91300 |
|
66 |
48 |
$0.00 |